YouTube video by lundimatin

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an early sign of promise

Guggenheim starts SLDB coverage with Buy rating and $26 price target. SGT-003 gene therapy shows safer profile vs Sarepta's Elevidys, eyes accelerated FDA approval.

Solid Biosciences’ gene therapy SGT-003 shows early promise for Duchenne; trial patients improved muscle and heart function, with potential accelerated FDA approval in 2026.

Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.

Click to view the official SEC document.

Solid Biosciences (Nasdaq: SLDB) reported second quarter 2026 results and clinical updates. Cash, cash equivalents and available-for-sale securities were $377.7 million as of June 30, 2026, up from $187.9 million at year-end 2025, with a cash runway expected to extend into mid-2028, according to the company.SGT-003 for Duchenne has been generally well tolerated in 53 participants in the Phase 1/2 INSPIRE DUCHENNE trial, and dosing has begun in the Phase 3 IMPACT DUCHENNE trial. Solid plans an FDA meeting in late Q4 2026 to seek guidance on a potential accelerated approval pathway. SGT-212 for Friedreich’s ataxia has shown no treatment-related serious adverse events in two dosed participants, with initial data expected in Q1 2027. SGT-501 for CPVT is in Phase 1b site-activation and screening, with first dosing targeted for 2H 2026. The company has executed 50+ agreements for its POLARIS-101™ capsid.Q2 2026 R&D expenses were $44.3 million and G&A expenses $13.1 million, leading to a net loss of $54.8 million, compared with a $39.5 million net loss in Q2 2025.